Imvotamab (IGM-2323), a CD20xCD3 bispecific IGM antibody featuring a dual-action mechanism, promotes physiological T cell activation to avoid both over-stimulation and immune function down-regulation. This compound is under development for addressing B-cell malignant tumors, including multiple myeloma (MM) and non-Hodgkins lymphoma (NHL) [1] [2] [3] [4].
CAS Number:
[2573121-53-4]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
